Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Study Assessing the Potential for Reduced Rates of Implant Failure Using Multi-Beam Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer Patients With Implant Reconstructions
Phase II Study Assessing the Potential for Reduced Rates of Implant Failure Using Multi-Beam Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer Patients With Implant Reconstructions
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering at Basking Ridge
mi
from
Basking Ridge, NJ
Study Assessing the Potential for Reduced Rates of Implant Failure Using Multi-Beam Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer Patients With Implant Reconstructions
Phase II Study Assessing the Potential for Reduced Rates of Implant Failure Using Multi-Beam Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer Patients With Implant Reconstructions
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering at Basking Ridge
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
Study Assessing the Potential for Reduced Rates of Implant Failure Using Multi-Beam Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer Patients With Implant Reconstructions
Phase II Study Assessing the Potential for Reduced Rates of Implant Failure Using Multi-Beam Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer Patients With Implant Reconstructions
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan-Kettering Cancer Center @ Suffolk
mi
from
Commack, NY
Study Assessing the Potential for Reduced Rates of Implant Failure Using Multi-Beam Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer Patients With Implant Reconstructions
Phase II Study Assessing the Potential for Reduced Rates of Implant Failure Using Multi-Beam Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer Patients With Implant Reconstructions
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan-Kettering Cancer Center @ Suffolk
mi
from
Commack, NY
Click here to add this to my saved trials
Study Assessing the Potential for Reduced Rates of Implant Failure Using Multi-Beam Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer Patients With Implant Reconstructions
Phase II Study Assessing the Potential for Reduced Rates of Implant Failure Using Multi-Beam Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer Patients With Implant Reconstructions
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Study Assessing the Potential for Reduced Rates of Implant Failure Using Multi-Beam Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer Patients With Implant Reconstructions
Phase II Study Assessing the Potential for Reduced Rates of Implant Failure Using Multi-Beam Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer Patients With Implant Reconstructions
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Study Assessing the Potential for Reduced Rates of Implant Failure Using Multi-Beam Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer Patients With Implant Reconstructions
Phase II Study Assessing the Potential for Reduced Rates of Implant Failure Using Multi-Beam Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer Patients With Implant Reconstructions
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Rockville Centre
mi
from
Rockville Centre, NY
Study Assessing the Potential for Reduced Rates of Implant Failure Using Multi-Beam Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer Patients With Implant Reconstructions
Phase II Study Assessing the Potential for Reduced Rates of Implant Failure Using Multi-Beam Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer Patients With Implant Reconstructions
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Rockville Centre
mi
from
Rockville Centre, NY
Click here to add this to my saved trials
Study Assessing the Potential for Reduced Rates of Implant Failure Using Multi-Beam Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer Patients With Implant Reconstructions
Phase II Study Assessing the Potential for Reduced Rates of Implant Failure Using Multi-Beam Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer Patients With Implant Reconstructions
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Monmouth
mi
from
Middletown, NJ
Study Assessing the Potential for Reduced Rates of Implant Failure Using Multi-Beam Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer Patients With Implant Reconstructions
Phase II Study Assessing the Potential for Reduced Rates of Implant Failure Using Multi-Beam Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer Patients With Implant Reconstructions
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Monmouth
mi
from
Middletown, NJ
Click here to add this to my saved trials
Study Assessing the Potential for Reduced Rates of Implant Failure Using Multi-Beam Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer Patients With Implant Reconstructions
Phase II Study Assessing the Potential for Reduced Rates of Implant Failure Using Multi-Beam Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer Patients With Implant Reconstructions
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Westchester
mi
from
Harrison, NY
Study Assessing the Potential for Reduced Rates of Implant Failure Using Multi-Beam Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer Patients With Implant Reconstructions
Phase II Study Assessing the Potential for Reduced Rates of Implant Failure Using Multi-Beam Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer Patients With Implant Reconstructions
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Westchester
mi
from
Harrison, NY
Click here to add this to my saved trials
Study Assessing the Potential for Reduced Rates of Implant Failure Using Multi-Beam Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer Patients With Implant Reconstructions
Phase II Study Assessing the Potential for Reduced Rates of Implant Failure Using Multi-Beam Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer Patients With Implant Reconstructions
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Nassau (Follow-Up only)
mi
from
Uniondale, NY
Study Assessing the Potential for Reduced Rates of Implant Failure Using Multi-Beam Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer Patients With Implant Reconstructions
Phase II Study Assessing the Potential for Reduced Rates of Implant Failure Using Multi-Beam Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer Patients With Implant Reconstructions
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Nassau (Follow-Up only)
mi
from
Uniondale, NY
Click here to add this to my saved trials
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated:  12/31/1969
University of Alabama Hematology Oncology Clinic at Medical West
mi
from
Birmingham, AL
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated: 12/31/1969
University of Alabama Hematology Oncology Clinic at Medical West
mi
from
Birmingham, AL
Click here to add this to my saved trials
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated:  12/31/1969
University of Florida Shands Cancer Center
mi
from
Gainesville, FL
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated: 12/31/1969
University of Florida Shands Cancer Center
mi
from
Gainesville, FL
Click here to add this to my saved trials
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated:  12/31/1969
University of Miami, Sylvester Comprehensive Cancer Center
mi
from
Miami, FL
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated: 12/31/1969
University of Miami, Sylvester Comprehensive Cancer Center
mi
from
Miami, FL
Click here to add this to my saved trials
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated:  12/31/1969
Memorial Breast Cancer Center: Memorial West
mi
from
Pembroke Pines, FL
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated: 12/31/1969
Memorial Breast Cancer Center: Memorial West
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated:  12/31/1969
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated: 12/31/1969
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated:  12/31/1969
University of Chicago Medicine
mi
from
Chicago, IL
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated: 12/31/1969
University of Chicago Medicine
mi
from
Chicago, IL
Click here to add this to my saved trials
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated:  12/31/1969
Fort Wayne Oncology & Hematology, Inc
mi
from
Fort Wayne, IN
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated: 12/31/1969
Fort Wayne Oncology & Hematology, Inc
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated:  12/31/1969
IU Health Goshen Hospital
mi
from
Goshen, IN
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated: 12/31/1969
IU Health Goshen Hospital
mi
from
Goshen, IN
Click here to add this to my saved trials
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated:  12/31/1969
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated: 12/31/1969
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated:  12/31/1969
Community Regional Cancer Center
mi
from
Indianapolis, IN
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated: 12/31/1969
Community Regional Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated:  12/31/1969
IU Health Arnett Cancer Center
mi
from
Lafayette, IN
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated: 12/31/1969
IU Health Arnett Cancer Center
mi
from
Lafayette, IN
Click here to add this to my saved trials
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated:  12/31/1969
Community Healthcare System: Monroe Medical Associates
mi
from
Munster, IN
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated: 12/31/1969
Community Healthcare System: Monroe Medical Associates
mi
from
Munster, IN
Click here to add this to my saved trials
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated:  12/31/1969
Meritus Center For Clinical Research
mi
from
Hagerstown, MD
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated: 12/31/1969
Meritus Center For Clinical Research
mi
from
Hagerstown, MD
Click here to add this to my saved trials
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated:  12/31/1969
Tufts Medical Center
mi
from
Boston, MA
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated: 12/31/1969
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated:  12/31/1969
Nebraska Cancer Specialists
mi
from
Omaha, NE
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated: 12/31/1969
Nebraska Cancer Specialists
mi
from
Omaha, NE
Click here to add this to my saved trials
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated:  12/31/1969
University of Cincinnati Cancer Institute
mi
from
Cincinnati, OH
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated: 12/31/1969
University of Cincinnati Cancer Institute
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated:  12/31/1969
Mercy Clinic Oncology & Hematology: McAuley
mi
from
Oklahoma City, OK
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated: 12/31/1969
Mercy Clinic Oncology & Hematology: McAuley
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated:  12/31/1969
Pinnacle Health Cancer Center
mi
from
Harrisburg, PA
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated: 12/31/1969
Pinnacle Health Cancer Center
mi
from
Harrisburg, PA
Click here to add this to my saved trials
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated:  12/31/1969
Joe Arrington Cancer Research and Treatment Center
mi
from
Lubbock, TX
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated: 12/31/1969
Joe Arrington Cancer Research and Treatment Center
mi
from
Lubbock, TX
Click here to add this to my saved trials
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated:  12/31/1969
Virginia Oncology Associates
mi
from
Norfolk, VA
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated: 12/31/1969
Virginia Oncology Associates
mi
from
Norfolk, VA
Click here to add this to my saved trials
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated:  12/31/1969
Froedtert and the Medical College of Wisconsin
mi
from
Milwaukee, WI
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated: 12/31/1969
Froedtert and the Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated:  12/31/1969
Aurora Health Care
mi
from
Wauwatosa, WI
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated: 12/31/1969
Aurora Health Care
mi
from
Wauwatosa, WI
Click here to add this to my saved trials
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated:  12/31/1969
Memorial Cancer Institute
mi
from
Hollywood, FL
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated: 12/31/1969
Memorial Cancer Institute
mi
from
Hollywood, FL
Click here to add this to my saved trials
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated:  12/31/1969
Community Hospital of Anderson and Madison County, Inc.
mi
from
Anderson, IN
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated: 12/31/1969
Community Hospital of Anderson and Madison County, Inc.
mi
from
Anderson, IN
Click here to add this to my saved trials
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated:  12/31/1969
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated: 12/31/1969
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Click here to add this to my saved trials
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated:  12/31/1969
Washington University: Siteman Cancer Center
mi
from
Saint Louis, MO
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated: 12/31/1969
Washington University: Siteman Cancer Center
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated:  12/31/1969
Erlanger Health System
mi
from
Chattanooga, TN
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated: 12/31/1969
Erlanger Health System
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated:  12/31/1969
Georgetown University- Lombardi Comprehensive Cancer Center
mi
from
Washington,
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated: 12/31/1969
Georgetown University- Lombardi Comprehensive Cancer Center
mi
from
Washington,
Click here to add this to my saved trials
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated:  12/31/1969
St Vincent Hospital
mi
from
Indianapolis, IN
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Status: Enrolling
Updated: 12/31/1969
St Vincent Hospital
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Weight Loss Plus Omega-3 Fatty Acids or Placebo in High Risk Women
Randomized Pilot Trial of Omega-3 Fatty Acids or Placebo in Peri- or Post-Menopausal Women at High Risk for Breast Cancer Undergoing a Weight Loss Intervention
Status: Enrolling
Updated:  12/31/1969
University of Kansas Medical Center, Breast Cancer Prevention Center
mi
from
Kansas City, KA
Weight Loss Plus Omega-3 Fatty Acids or Placebo in High Risk Women
Randomized Pilot Trial of Omega-3 Fatty Acids or Placebo in Peri- or Post-Menopausal Women at High Risk for Breast Cancer Undergoing a Weight Loss Intervention
Status: Enrolling
Updated: 12/31/1969
University of Kansas Medical Center, Breast Cancer Prevention Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread
A Phase 2 Study of LY2835219 for Patients With Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Northern Arizona Hematology & Oncology Associates
mi
from
Sedona, AZ
A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread
A Phase 2 Study of LY2835219 for Patients With Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Northern Arizona Hematology & Oncology Associates
mi
from
Sedona, AZ
Click here to add this to my saved trials
A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread
A Phase 2 Study of LY2835219 for Patients With Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Arizona Clinical Research Center
mi
from
Tucson, AZ
A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread
A Phase 2 Study of LY2835219 for Patients With Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Arizona Clinical Research Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread
A Phase 2 Study of LY2835219 for Patients With Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
HOPE Hematology Oncology Physicians and Extenders
mi
from
Tucson, AZ
A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread
A Phase 2 Study of LY2835219 for Patients With Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
HOPE Hematology Oncology Physicians and Extenders
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread
A Phase 2 Study of LY2835219 for Patients With Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Sansum Medical Research Foundation
mi
from
Santa Barbara, CA
A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread
A Phase 2 Study of LY2835219 for Patients With Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Sansum Medical Research Foundation
mi
from
Santa Barbara, CA
Click here to add this to my saved trials
A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread
A Phase 2 Study of LY2835219 for Patients With Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Rocky Mountain Cancer Center
mi
from
Denver, CO
A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread
A Phase 2 Study of LY2835219 for Patients With Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Rocky Mountain Cancer Center
mi
from
Denver, CO
Click here to add this to my saved trials
A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread
A Phase 2 Study of LY2835219 for Patients With Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Florida Cancer Specialists
mi
from
Fort Myers, FL
A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread
A Phase 2 Study of LY2835219 for Patients With Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Florida Cancer Specialists
mi
from
Fort Myers, FL
Click here to add this to my saved trials
A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread
A Phase 2 Study of LY2835219 for Patients With Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Advanced Medical Specialties
mi
from
Miami, FL
A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread
A Phase 2 Study of LY2835219 for Patients With Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Advanced Medical Specialties
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread
A Phase 2 Study of LY2835219 for Patients With Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Maryland Oncology Hematology PA
mi
from
Columbia, MD
A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread
A Phase 2 Study of LY2835219 for Patients With Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Maryland Oncology Hematology PA
mi
from
Columbia, MD
Click here to add this to my saved trials
A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread
A Phase 2 Study of LY2835219 for Patients With Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread
A Phase 2 Study of LY2835219 for Patients With Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread
A Phase 2 Study of LY2835219 for Patients With Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Minnesota Oncology and Hematology, PA
mi
from
Minneapolis, MN
A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread
A Phase 2 Study of LY2835219 for Patients With Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Minnesota Oncology and Hematology, PA
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread
A Phase 2 Study of LY2835219 for Patients With Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Oncology Hematology Care
mi
from
Cincinnati, OH
A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread
A Phase 2 Study of LY2835219 for Patients With Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Oncology Hematology Care
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread
A Phase 2 Study of LY2835219 for Patients With Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Sarah Cannon Research Institute (SCRI)
mi
from
Nashville, TN
A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread
A Phase 2 Study of LY2835219 for Patients With Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Sarah Cannon Research Institute (SCRI)
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread
A Phase 2 Study of LY2835219 for Patients With Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Texas Oncology Cancer Center
mi
from
Austin, TX
A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread
A Phase 2 Study of LY2835219 for Patients With Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Texas Oncology Cancer Center
mi
from
Austin, TX
Click here to add this to my saved trials